According to CoinMeta, AI drug discovery company Isomorphic Labs is in talks for a new round of financing worth approximately $5 billion, with a valuation that could reach $50 billion. Sources indicate that the financing has not yet been finalized, and details may change. Isomorphic Labs was spun off from Google DeepMind by Demis Hassabis in 2021 and is headquartered in London. Its core business is to use AI (based on technologies such as AlphaFold) to accelerate drug design and discovery. The company recently completed a $2.1 billion Series B financing in May this year, led by Thrive Capital with participation from Alphabet among others. Bloomberg previously reported that the company was in the early stages of financing negotiations, with a valuation range of $40 billion to $50 billion. Currently, the company is still in the pre-clinical phase, and Hassabis indicates that it is expected to enter its first clinical trials by the end of 2026.